Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from BioNTech SE

Pfizer, Moderna, BioNTech Stocks Tumble After Report Of Plan To Link COVID Vaccines To Child Deaths

Shares of COVID-19 vaccine makers Pfizer Inc (NYSE:PFE), BioNTech SE ADR (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are trading lower Friday following a Washington Post report that Trump administration health officials intend to link the vaccines to 25 child deaths. This assertion is reportedly based on unverified submissions to the Vaccine…

Benzinga

Is BioNTech Stock a Buy on Major $11 Billion Cancer-Drug Deal?

With BioNTech sealing a blockbuster $11 billion cancer deal with Bristol-Myers Squibb, should investors be loading up on this rising biotech star?

Barchart

3 Specialty Healthcare Providers Addressing Niche Markets

The healthcare industry is poised for growth driven by the rapid adoption of new and advanced medical technologies to enhance diagnosis. Hence, investors might consider investing in healthcare stocks, such as Agilent Technologies (A), BioNTech (BNTX), and STERIS (STE), which address niche markets. Read more….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Biotech Stocks Revolutionizing Healthcare

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and transformative partnerships. To capitalize on this trend, consider adding Amgen (AMGN), BioNTech (BNTX), and Gilead Sciences (GILD), which could boost your portfolio.

StockNews.com

3 Genomic Stocks Unlocking the Secrets of DNA

Genomics is becoming the future of medicine as technological advancements continue to unlock our DNA’s vast potential. Given this backdrop, investing in fundamentally sound genomics stocks like Illumina (ILMN), BioNTech (BNTX), and Bio-Techne Corp. (TECH) could be beneficial. Read more….

StockNews.com

3 Biotech Stocks to Watch in March for Success

The biotech industry is set for strong growth amid the growing need for personalized treatments, the rising number of chronic diseases, increased investment in research, and the use of advanced technologies. Therefore, investors could consider adding fundamentally strong biotech stocks Acorda Therapeutics (ACOR), BioNTech (BNTX), and Jazz Pharmaceuticals (JAZZ) to…

StockNews.com

3 Biotech Stock Sensations to Snatch up This Week

The future of the biotech industry appears promising, fueled by technology-driven advancements, increasing merger and acquisition maneuvers, and developing product pipelines. Given this backdrop, quality biotech stocks BioNTech SE (BNTX), Entrada Therapeutics (TRDA), and Incyte Corporation (INCY) could be wise to snatch up this week. Read on….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Buy, Hold, or Sell? Analyzing 3 Biotech Stocks Investors Are Watching

Amid the use of advanced technologies, personalized medicines, demand for quality treatments and therapies, and an aging population, the biotech industry appears to be on a steady path for expansion. Given this backdrop, let’s analyze the fundamentals of Biogen (BIIB), BioNTech (BNTX), and Kura (KURA) to determine which of these…

StockNews.com

3 Biotech Stocks Offering Great Potential for Gains in October

The biotechnology sector has grown exceptionally, primarily driven by innovations that consistently establish the industry as a leading force in vital spheres such as healthcare, agriculture, and environmental equilibrium. Given the industry’s solid prospects, quality biotech stocks BioNTech (BNTX), Puma Biotechnology (PBYI), and Protalix BioTherapeutics (PLX) could be wise portfolio…

StockNews.com

3 Buy Worthy Biotech Stocks for May

The biotech industry is well-positioned to witness significant growth with government support and breakthrough developments. Therefore, biotech stocks BioNTech SE (BNTX), Acorda Therapeutics (ACOR), and Shionogi (SGIOY) might be solid buys. Read on.

StockNews.com

4 Biotech Stocks to Keep an Eye on in 2023

The U.S. 2022 fourth-quarter GDP growth surpassed estimates and induced fresh optimism. On the other hand, the biotech industry is expected to witness robust demand despite macro uncertainties. So, given the stable prospects of the biotech sector, quality stocks Amgen (AMGN), BioNTech (BNTX), Exelixis (EXEL), and Taisho Pharmaceutical (TAIPY) could…

StockNews.com

Updated COVID vaccines prevented illness from latest variants -CDC

The updated COVID-19 boosters from Pfizer Inc/BioNTech SE and Moderna helped prevent symptomatic infections against the new XBB-related subvariants, offering new evidence of how the vaccines perform against these fast-spreading strains, U.S. officials said on Wednesday.

Reuters

BioNTech signs deal with UK for personalised cancer therapies

BioNTech SE has signed a deal with the UK government to enrol up to 10,000 patients in clinical trials by the end of 2030 for personalised cancer therapies, the German drug maker said.

Reuters

Pfizer/BioNTech's updated COVID shot shows strong response against BQ.1.1

Pfizer Inc and its German partner BioNTech SE said on Friday their Omicron-tailored shot produced higher virus-neutralizing antibodies in older adults against the emerging subvariant BQ.1.1 than its original vaccine.

Reuters

Get all your
news in one place.

100’s of premium titles.
One news app.

Reuters

Pfizer, BioNTech start COVID-flu combination vaccine study

U.S. drugmaker Pfizer Inc and its German partner BioNTech SE have started an early-stage study to evaluate a combination vaccine targeting COVID-19 and influenza, the companies said on Thursday.

Benzinga

Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ (NASDAQ:SPPI) lead asset ROLVEDON (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia. Spectrum Pharmaceuticals shares traded as high as 3.17 percent, in a range of $1.21 to $1.30 on day volume of 6.8 million…

Benzinga

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ (NASDAQ:NTLA) lead asset NTLA-2002, for the treatment of hereditary angioedema (HAE). Intellia shares traded in a range of $56.52 to $60.06 on day volume of 901.43 thousand shares, closed regular trading session at $59.97. The company…

Tribune News Service

FDA clears way for boosters targeted at latest COVID variants

COVID-19 boosters from Moderna Inc. and the partnership of Pfizer Inc. and BioNTech SE that are tailored to the latest COVID-19 omicron variants got U.S. regulatory clearance, a move toward additional protection as concern grows about potential new waves in the fall and winter.

Get all your
news in one place.

100’s of premium titles.
One news app.

Tribune News Service

Moderna sues Pfizer, BioNTech over COVID vaccine technology

Moderna Inc. sued Pfizer Inc. and BioNTech SE, claiming the technology in their COVID-19 shot infringes on its patents, a move that sets the stage for a massive legal clash between the vaccine titans.

Benzinga

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has announced clearance to Insulet’s (NASDAQ:PODD) Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for individuals aged two years and older with type 1 diabetes (T1D). Insulet shares traded in a range of $260.13 to $266.73 on day volume of 200.86 thousand shares…

Tribune News Service

Pfizer files application for booster against latest variants

Pfizer Inc. and BioNTech SE asked the U.S. to authorize a new COVID-19 booster shot customized against the currently circulating COVID-19 variants as governments race to protect their populations against the ever-mutating virus.

StockNews.com

5 Biotech Stocks to Buy and Hold for the Next Decade

The biotech industry seems poised to witness solid growth over the next decade with intensive innovation, breakthrough developments, and growing investments in the sector. So, given analysts’ promising growth outlook for the industry, it could be wise for investors to buy and hold fundamentally solid biotech stocks Vertex Pharmaceuticals (VRTX),…

Benzinga

FDA Expert Panel Favors COVID-19 Boosters Targeting Omicron BA.4, BA.5 Subvariants

The FDA's independent experts voted to include a SARS-CoV-2 omicron component in COVID-19 vaccines that would be used for boosters in the U.S. beginning in fall 2022. The panel has advised manufacturers to develop modified vaccines that add an omicron BA.4/5 spike protein component to the current vaccine composition to create a…

Benzinga

Why BioNTech Stock Is Surging

BioNTech SE (NASDAQ: BNTX) shares are trading higher Thursday after the company and Pfizer Inc (NYSE: PFE) announced a new COVID-19 vaccine supply agreement with the U.S. government.

Benzinga

Why Pfizer Stock Is Rising Today

Pfizer Inc (NYSE: PFE) shares are trading higher Thursday after the company and BioNTech SE (NASDAQ: BNTX) announced a new COVID-19 vaccine supply agreement with the U.S. government.

1 2 3 4

People

Donald Trump

138,732 stories

Dipanjan BanchurSince

722 stories

Sristi Suman JayaswalThe

216 stories

Neha PanjwaniFrom

97 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.